FDA Panel Backs Palovarotene for Ultra-Rare Bone Disorder

(MedPage Today) -- Despite lingering concerns over post hoc analyses, palovarotene won the support of an FDA panel as a treatment for abnormal bone growth due to fibrodysplasia ossificans progressiva (FOP). By a vote of 10-4, members of the Endocrinologic...
Source: MedPage Today Public Health - Category: American Health Source Type: news